Anastasios Raptis

Anastasios Raptis practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania.

Anastasios Raptis' NPI, 1962475509, was assigned on February 13, 2006. Anastasios Raptis holds Pennsylvania license MD425540.

Anastasios Raptis' primary practice is UPMC Magee-Womens Hospital, at 300 Halket St, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 432-5500.

Anastasios Raptis' primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Anastasios Raptis to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Anastasios Raptis practices. Vendor and product names are available with a free account.

Hematology and oncology is Anastasios Raptis' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Anastasios Raptis is licensed in Pennsylvania.

CMS data shows 1,253 Medicare services from Anastasios Raptis across 8 procedure codes in 2024, for 249 Medicare patients. Medicare paid $90,010 for them.

CMS counts 249 Medicare patients who saw Anastasios Raptis in 2024. The largest group is 65 to 74, with 141 patients. 73% of them have high blood pressure, and 72% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Anastasios Raptis' median patient age at 72, with 47% women.

In 2024, Anastasios Raptis wrote 1,599 Medicare Part D claims for 148 patients. 71% of them were for generic drugs. CMS names the drug for 1,430 of them, across 30 drugs with 11 or more claims each, at $5,697,201 in total drug cost. In 2023, CMS named 1,549 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Anastasios Raptis for performance year 2024, reported as part of a group.

Dmand AI links 34 papers to Anastasios Raptis, published from 2010 to 2024. 2017 was the busiest year, with 5. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Hematopoietic Stem Cell Transplantation. Anastasios Raptis has published most often in Oncol Res. Anastasios Raptis' most frequent co-authors are Mounzer E. Agha, MD, Kathleen Anne Dorritie, MD and Alison R. Sehgal.

Dmand AI links Anastasios Raptis to 3 clinical trials. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Primary Myelofibrosis.

CMS Open Payments shows 39 general payments to Anastasios Raptis from 10 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Bristol-Myers Squibb Company paid the most, $31,478.